胃動力障礙治療市場規模、佔有率和成長分析：按藥物類別、適應症、給藥途徑、分銷管道、患者類型和地區分類－2026-2033年產業預測

2024 年全球胃動力障礙市場價值為 280 萬美元，預計到 2025 年將成長至 296 萬美元，到 2033 年將成長至 465 萬美元，在預測期（2026-2033 年）內複合年成長率為 5.8%。

全球胃動力障礙市場的主要驅動力是功能性胃腸疾病發生率的上升，而這又與人口老化和生活方式的改變密切相關。該市場涵蓋多種旨在促進排放和調節腸神經系統功能的藥物和生物製藥，用於治療胃麻痺和慢性噁心等疾病。胃動力減弱會對生活品質產生負面影響，並增加醫療保健成本，因此吸引了保險公司和醫療服務提供者的注意。尤其值得一提的是，針對特定機制的療法正日益受到重視，這推動了實證醫學證據的產生和臨床應用的良性循環。對後期臨床試驗的投資和簡化的監管流程進一步推動了市場成長，而人工智慧技術則提高了標靶發現、試驗效率和患者分層能力，從而吸引了投資並加速了該領域的發展。

全球胃動力障礙治療市場的成長要素

全球胃動力障礙治療市場的主要促進因素之一是全球胃腸道疾病盛行率的不斷上升，這顯著增加了對有效治療方法的需求。飲食習慣的改變、壓力水平的增加以及久坐的生活方式等因素，都導致了胃麻痺和功能性消化不良等疾病的發病率上升。此外，醫護人員和患者對胃腸道疾病的認知不斷提高，也推動了對創新治療方法的需求。藥物研發的持續進步和標靶治療的引入進一步刺激了市場成長，使患者能夠獲得更有效、更個人化的治療方案，從而改善胃動力。

全球胃動力障礙治療市場面臨的限制因素

全球胃動力障礙治療市場的主要限制因素之一是嚴格的法規環境，該環境規範藥物核准和臨床評估。檢驗新治療方法的安全性和有效性是一個複雜且耗時的過程，這可能會阻礙創新治療方法的引入。此外，高昂的研發成本以及大規模臨床試驗的需求，使得製藥公司對投資這一細分領域猶豫不決。另外，胃動力障礙患者治療反應的個別差異也使藥物研發更加複雜，並為建立一致的治療效果和獲得市場認可帶來了挑戰。

全球胃動力障礙治療市場趨勢

全球胃動力障礙治療市場正經歷著向精準醫療的重大轉變，製藥公司日益專注於提供針對個別患者表現型、生物標記和基因譜的客製化治療方法。這一趨勢促進了診斷公司和製藥企業之間更緊密的合作，以提高患者選擇的準確性，最大限度地減少試驗差異，並展現更具說服力的臨床效益。隨著支付者和醫療服務提供者對標靶治療在改善症狀管理和提高治療依從性方面表現出越來越濃厚的興趣，法律規範也在進行調整，以支持伴隨診斷的整合。這項發展將鼓勵對分層臨床試驗的投資，並最終為創新治療方法更有效率的商業化鋪平道路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胃動力障礙治療藥物市場規模：依藥物類別分類

• 胃動力促效劑
  • 多巴胺拮抗劑
  • 血清素受體促效劑
  • 胃動素受體促效劑
  • Ghrelin促效劑
  • 其他
• 止吐藥
  • 血清素（5-HT3）拮抗劑
  • 多巴胺拮抗劑
  • 神經激肽-1 (NK1) 拮抗劑
  • 抗組織胺和抗膽鹼能藥
  • 其他
• 瀉藥和便秘療法
  • 滲透性瀉藥
  • 刺激性瀉藥
  • 促分泌藥物
  • 氯離子通道活化劑
  • 鳥苷酸環化酶C促效劑
  • 其他
• 止瀉藥
  • 鴉片受體促效劑
  • 分泌抑制劑
  • 膽汁酸調節劑
  • 其他
• 抑酸治療和輔助性治療
  • 質子幫浦阻斷劑（PPI）
  • H2受體拮抗劑
  • 黏膜保護劑
  • 其他

全球胃動力障礙治療市場規模：依疾病適應症分類

• 胃輕癱
• 慢性特發性便秘
• 伴隨運動功能障礙的大腸激躁症（IBS）
• 功能性消化不良
• 與胃食道逆流症 (GERD) 相關的運動障礙
• 術後腸阻塞
• 慢性腹瀉及相關運動功能障礙
• 其他

全球胃動力障礙治療藥物市場規模：依給藥途徑分類

• 口服
• 注射/腸外給藥
• 直腸
• 經皮

全球胃動力障礙治療市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球胃動力障礙治療市場規模：依患者類型分類

• 成人
• 兒童
• 老年人

全球胃動力障礙治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Takeda Pharmaceutical Company
• Abbott Laboratories
• Janssen Pharmaceuticals
• Novartis
• Evoke Pharma
• Bausch Health Companies
• GlaxoSmithKline
• Pfizer
• AstraZeneca
• Theravance Biopharma
• Renexxion
• CinDome Pharma
• AbbVie
• Teva Pharmaceutical Industries
• Sanofi
• Bayer
• Cadila Pharmaceuticals
• Alfasigma
• Chugai Pharmaceutical
• Dr. Falk Pharma

結論與建議

Global Gastric Motility Disorder Drug Market size was valued at USD 2.8 Million in 2024 and is poised to grow from USD 2.96 Million in 2025 to USD 4.65 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global gastric motility disorder drug market is primarily driven by the increasing incidence of functional gastrointestinal disorders, fueled by an aging population and evolving lifestyles. This market includes various pharmaceuticals and biologics aimed at enhancing gastric emptying and aligning enteric nervous system functions for conditions like gastroparesis and chronic nausea. Impaired gastric motility negatively impacts quality of life and escalates healthcare costs, fostering interest from payers and healthcare providers. Notably, there is a significant focus on mechanism-targeted therapeutics, which supports a cycle of evidence generation and clinical adoption. Investments in late-stage trials and streamlined regulatory pathways further promote market growth, while AI technology is enhancing target discovery, trial efficiency, and patient stratification, attracting investment and expediting development in this space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Motility Disorder Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Motility Disorder Drug Market Segments Analysis

Global gastric motility disorder drug market is segmented by drug class, disease indication, route of administration, distribution channel, patient type and region. Based on drug class, the market is segmented into Prokinetic Agents, Antiemetic Agents, Laxatives & Constipation Therapies, Antidiarrheal Agents and Acid Suppression & Adjunct Therapies. Based on disease indication, the market is segmented into Gastroparesis, Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS) with Motility Disorders, Functional Dyspepsia, Gastroesophageal Reflux Disease (GERD) Associated Motility Disorders, Post-Operative Ileus, Chronic Diarrhea & Related Motility Disorders and Others. Based on route of administration, the market is segmented into Oral, Injectable/Parenteral, Rectal and Transdermal. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on patient type, the market is segmented into Adult, Pediatric and Geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Motility Disorder Drug Market

One of the key market drivers for the Global Gastric Motility Disorder Drug Market is the rising prevalence of gastrointestinal disorders worldwide, which has significantly increased the demand for effective treatment options. Factors such as changing dietary habits, increased stress levels, and sedentary lifestyles contribute to a growing incidence of conditions like gastroparesis and functional dyspepsia. Additionally, heightened awareness among healthcare professionals and patients about gastrointestinal disorders fuels the demand for innovative therapeutics. The ongoing advancements in drug development and the introduction of targeted therapies further stimulate market growth, ensuring that patients receive more effective and personalized treatment options for improving gastric motility.

Restraints in the Global Gastric Motility Disorder Drug Market

One key market restraint for the global gastric motility disorder drug market is the stringent regulatory environment governing drug approvals and clinical evaluations. The complex and time-consuming processes involved in testing the safety and efficacy of new therapies can hinder the introduction of innovative treatments. Furthermore, the high costs associated with research and development, coupled with the need for extensive clinical trials, deter pharmaceutical companies from investing in this niche area. In addition, the variability in treatment responses among patients with gastric motility disorders complicates drug development, leading to challenges in establishing consistent therapeutic outcomes and market acceptance.

Market Trends of the Global Gastric Motility Disorder Drug Market

The Global Gastric Motility Disorder Drug market is witnessing a significant shift towards precision medicine, as pharmaceutical developers increasingly focus on tailoring therapies to individual patients' phenotypes, biomarkers, and genetic profiles. This trend fosters enhanced collaboration between diagnostic firms and drug manufacturers, aiming to refine patient selection, minimize trial variability, and demonstrate more compelling clinical benefits. As payers and healthcare providers express heightened interest in targeted treatments for improved symptom management and treatment adherence, regulatory frameworks are adapting to support the integration of companion diagnostics. This evolution encourages investments in stratified clinical trials, ultimately paving the way for more efficient commercialization of innovative therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gastric Motility Disorder Drug Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Prokinetic Agents
  • Dopamine Antagonists
  • Serotonin Receptor Agonists
  • Motilin Receptor Agonists
  • Ghrelin Agonists
  • Others
• Antiemetic Agents
  • Serotonin (5-HT3) Antagonists
  • Dopamine Antagonists
  • Neurokinin-1 (NK1) Antagonists
  • Antihistamines & Anticholinergics
  • Others
• Laxatives & Constipation Therapies
  • Osmotic Laxatives
  • Stimulant Laxatives
  • Secretagogues
  • Chloride Channel Activators
  • Guanylate Cyclase-C Agonists
  • Others
• Antidiarrheal Agents
  • Opioid Receptor Agonists
  • Antisecretory Agents
  • Bile Acid Modulators
  • Others
• Acid Suppression & Adjunct Therapies
  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Antagonists
  • Mucosal Protective Agents
  • Others

Global Gastric Motility Disorder Drug Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Gastroparesis
• Chronic Idiopathic Constipation
• Irritable Bowel Syndrome (IBS) with Motility Disorders
• Functional Dyspepsia
• Gastroesophageal Reflux Disease (GERD) Associated Motility Disorders
• Post-Operative Ileus
• Chronic Diarrhea & Related Motility Disorders
• Others

Global Gastric Motility Disorder Drug Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable/Parenteral
• Rectal
• Transdermal

Global Gastric Motility Disorder Drug Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gastric Motility Disorder Drug Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Adult
• Pediatric
• Geriatric

Global Gastric Motility Disorder Drug Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Indication, Route of Administration, Distribution Channel, Patient Type)
  • US
  • Canada
• Europe (Drug Class, Disease Indication, Route of Administration, Distribution Channel, Patient Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Indication, Route of Administration, Distribution Channel, Patient Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Indication, Route of Administration, Distribution Channel, Patient Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Indication, Route of Administration, Distribution Channel, Patient Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evoke Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renexxion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CinDome Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alfasigma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Falk Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations